Enzymatic kinetics for Michaelis-Menten enzymes.
Diabetes mellitus (DM) is a common group of chronic metabolic diseases characterized by hyperglycemia, resulting from insufficient insulin secretion or inefficient utilization of insulin. The chronic hyperglycemia of diabetes causes serious damage to many of the body’s organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Therefore, control of postprandial blood glucose level is critical for treatment of diabetes and for reducing chronic vascular complications.
α-Glucosidase is an enzyme of the intestinal brush border, which catalyze the final step in the digestive process of carbohydrates to release absorbable monosaccharides resulting in increased blood glucose levels. Thus, inhibition of α-glucosidase can significantly delay carbohydrate digestion and glucose absorption, resulting in reduced postprandial plasma glucose levels and suppression of postprandial hyperglycemia. Therefore, α-glucosidase has been recognized as a therapeutic target for the treatment type-2 diabetes mellitus. α-Glucosidase inhibitors (acarbose, miglitol, voglibose) have been widely used in clinic for treatment of patients with type 2 diabetes. However, these classic α-glucosidase inhibitors cause various side effects including bloating, flatulence, diarrhea, abdominal discomfort, and pain. Hence, the search of novel α-glucosidase inhibitors with better activity and fewer side effects is still in progress. Read more...
7k inhibitor docked to 3a4a.pdb Show the structure of these inhibitors |